- Home
- NEWP vs VNDA Comparison
NEWP vs VNDA Comparison
Compare NEWP & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEWP
- VNDA
- Stock Information
- Founded
- NEWP 1972
- VNDA 2002
- Country
- NEWP Canada
- VNDA United States
- Employees
- NEWP N/A
- VNDA N/A
- Industry
- NEWP
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- NEWP
- VNDA Health Care
- Exchange
- NEWP Nasdaq
- VNDA Nasdaq
- Market Cap
- NEWP 199.1M
- VNDA 237.9M
- IPO Year
- NEWP N/A
- VNDA 2006
- Fundamental
- Price
- NEWP $1.44
- VNDA $4.33
- Analyst Decision
- NEWP Strong Buy
- VNDA Strong Buy
- Analyst Count
- NEWP 1
- VNDA 3
- Target Price
- NEWP $5.00
- VNDA $15.33
- AVG Volume (30 Days)
- NEWP 262.4K
- VNDA 519.0K
- Earning Date
- NEWP 05-07-2025
- VNDA 05-07-2025
- Dividend Yield
- NEWP N/A
- VNDA N/A
- EPS Growth
- NEWP N/A
- VNDA N/A
- EPS
- NEWP N/A
- VNDA N/A
- Revenue
- NEWP N/A
- VNDA $201,351,000.00
- Revenue This Year
- NEWP N/A
- VNDA $16.86
- Revenue Next Year
- NEWP N/A
- VNDA $39.78
- P/E Ratio
- NEWP N/A
- VNDA N/A
- Revenue Growth
- NEWP N/A
- VNDA 13.37
- 52 Week Low
- NEWP $0.93
- VNDA $3.81
- 52 Week High
- NEWP $2.11
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- NEWP 66.49
- VNDA 50.43
- Support Level
- NEWP $1.35
- VNDA $4.30
- Resistance Level
- NEWP $1.46
- VNDA $4.42
- Average True Range (ATR)
- NEWP 0.08
- VNDA 0.16
- MACD
- NEWP 0.02
- VNDA 0.03
- Stochastic Oscillator
- NEWP 96.23
- VNDA 69.44
About NEWP New Pacific Metals Corp.
New Pacific Metals Corp is a Canadian Mining Issuer, in the business of exploring and developing precious metal properties in Bolivia. The company's projects which are also its reportable segments include Silver Sand; Carangas and Silverstrike.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.